NT_1170x120_1-11-18

Andreas Barner

Sanofi, Boehringer Ingelheim mull business swap

Sanofi, Boehringer Ingelheim mull business swap

NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).

Hikma to buy Roxane for $2.65 billion

Hikma to buy Roxane for $2.65 billion

LONDON — Hikma Pharmaceuticals PLC, a fast growing multinational pharmaceutical group, plans to acquire Roxane Laboratories from Boehringer Ingelheim in a deal valued at $2.65 billion. Hikma said the agreement stands to transform its position in the U.S. generic drug market, establishing the company as the sixth-largest generics maker by revenue. The addition of Roxane